5-Fluorouracil, Leucovorin, Ifosfamide and Cisplatin (FLIP) Combination Chemotherapy for Adevanced Non-Small Cell Lung Cancer / 대한암학회지
Journal of the Korean Cancer Association
;
: 46-52, 1997.
Article
Dans Coréen
| WPRIM
| ID: wpr-224329
ABSTRACT
PURPOSE:
To evaluate the response rate and toxicity of combination chemotherapy including 5-fluorouracil (F), leucovorin (L), ifosfamide (I) and cisplatin (P) for the previously untreated patients with unresectable stage IIIB or IV non-small cell lung cancer. MATERIALS ANDMETHOD:
The doses of FLIP were 5-fluorouracil 800 mg/m2 CI days 1-5, leucovorin 20 mg/m2 IV days 1-5, ifosfamide 1000 mg/m2 CI days 1-3, cisplatin 100 mg/m2 IV day 1 respectively. Cycles were repeated every 3 weeks until disease progression. Seventy-three previously untreated patients were enrolled. Age ranged from 30 to 73 (median 56 years); 43 were male, 30 female. Fifty-three patients had performance status (ECOG) 0-1 and 19 performance status 2. Twenty-two patients had stage IIIB and 51 stage IV. Follow-up ranged from 7+ to 160weeks (median 57 weeks).RESULTS:
The overall response rate was 46.7% for 62 evaluable patients. (CR 1 patient, PR 28 patients) Median response duration was 24 weeks (range 1+ to 36+ weeks). Toxicity > Grade II (WHO) included granulocytopenia 19.8%, anemia 13.5%, nausea and vomiting 31.5% stomatitis 46.5%, neuropathy 24.6%.CONCLUSION:
FLIP chemotherapy was comparable to other combination chemotherapy for advanced non-small cell lung cancer with moderate toxicities.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Stomatite
/
Vomissement
/
Leucovorine
/
Études de suivi
/
Cisplatine
/
Carcinome pulmonaire non à petites cellules
/
Évolution de la maladie
/
Agranulocytose
/
Traitement médicamenteux
/
Association de médicaments
Type d'étude:
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Coréen
Texte intégral:
Journal of the Korean Cancer Association
Année:
1997
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS